Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16

Rhea-AI Summary

Delcath Systems, Inc. (NASDAQ: DCTH) is set to participate in the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference from February 14 to 16, 2023, in Snowbird, Utah. CEO Gerard Michel will hold one-on-one meetings during the event. The company specializes in treating primary and metastatic liver cancers, utilizing its percutaneous hepatic perfusion (PHP) system to deliver high-dose chemotherapy while minimizing side effects. In the U.S., the PHP system is under development as HEPZATO™ KIT for metastatic ocular melanoma, while in Europe, it's marketed as CHEMOSAT.

News Market Reaction – DCTH

-1.60%

-1.60% Session move

In the trading session that priced this news, DCTH declined 1.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16.

Delcath CEO, Gerard Michel will be conducting one-on-one meetings. To request a one-on-one meeting please contact your BTIG representative with interest.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO™ KIT (melphalan hydrochloride for injection/Hepatic Delivery System), or HEPZATO, for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated as a drug by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-btig-medtech-digital-health-life-sciences--diagnostic-tools-conference-on-february-14-to-16-301733027.html

SOURCE Delcath Systems, Inc.

FAQ

What is Delcath Systems, Inc. participating in on February 14 to 16, 2023?

Delcath Systems, Inc. will participate in the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference.

Who is the CEO of Delcath Systems, Inc.?

The CEO of Delcath Systems, Inc. is Gerard Michel.

What is the purpose of Delcath's percutaneous hepatic perfusion system?

The PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and related side effects.

What is HEPZATO™ KIT developed for?

HEPZATO™ KIT is developed for treating patients with unresectable hepatic-dominant metastatic ocular melanoma.

What is CHEMOSAT and where is it approved?

CHEMOSAT is the name for Delcath's PHP system in Europe, approved as a Class III medical device for treating various liver cancers.